Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

Video

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

In a randomized controlled phase III study, investigators evaluated the impact of secondary cytoreductive surgery in patients with recurrent ovarian cancer.

Related Videos
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Related Content
Oliver Dorigo, MD, PhD

Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

April 22nd 2024
Article
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023
Podcast
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust, NIHR Guy’s Clinical Research Facility

First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer

April 14th 2024
Article
Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022
Podcast
Debra L. Richardson, MD, FACS, FACOG, associate professor, chief, Section of Gynecologic Oncology and Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma (OU) College of Medicine, OU Health

Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer

April 4th 2024
Article
The FDA has approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously received one to three systemic treatment regimens.

FDA Grants Full Approval to Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024
Article